Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCRβ-directed CAR-T cells
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TCRβ-directed CAR-T cells are an investigational cell therapy designed to treat T-cell malignancies, such as T-cell leukemia and T-cell lymphoma. This approach involves engineering T cells to express a chimeric antigen receptor (CAR) that specifically targets the T-cell receptor beta (TCRβ) chain. A key strategy in this field involves targeting one of the two mutually exclusive TCRβ constant regions (TRBC1 or TRBC2). Because a single T-cell clone (including malignant ones) expresses only one of these regions, targeting the specific TRBC involved in the malignancy can eliminate the cancer cells while preserving the healthy T-cell population that expresses the alternative TRBC, thereby reducing the risk of total T-cell aplasia and severe immunosuppression. This specific program is being evaluated in Phase 1 clinical trials by Xiamen University.
- Other names
- TCRβ-targeted CAR-T cellsanti-TCRβ CAR-T cellsT-cell receptor beta-directed CAR-T cells
02
Targets
TRBV (T-cell receptor beta variable chain family)
Beyond the preview
Go deeper on TCRβ-directed CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCRβ-directed CAR-T cells.